- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00714623
The SCRIPPS DES REAL WORLD Registry
A Prospective Registry for the Use of CypherTM Sirolimus-Eluting Stents In Patients With Coronary Artery Disease Treated With Percutaneous Coronary Interventions at Scripps Clinic
This study is a prospective, non-randomized, open-label registry of consecutive patients with CAD treated by stent-assisted PCI using at least one CypherTM stent. Up to 1000 pts will be included in the registry. The registry is conducted for the evaluation of the impact of CypherTM Sirolimus-eluting stent implantation in the "real world" of interventional cardiology. Informed consent will be obtained from patients meeting the inclusion criteria before the initiation of any study specific procedures. Consecutive patients treated with the use of the CypherTM stent will be included in the registry. Baseline and post-procedure blood samples will be used to perform platelet function analysis using the Accumetrics Ultegra RPFA (Rapid Platelet Function Assay).
All patients will be followed from enrollment through the hospital discharge for any clinically significant event (death, myocardial infarction, TLR, TVR, major or minor bleeding). A follow-up telephone assessment of death, myocardial infarction, revascularization, and medical treatment will be conducted by experienced research personnel at 30 days, 6 months, 1 year and at least 2 years. All site reported deaths, myocardial infarctions and revascularizations will be adjudicated by an independent Clinical Events Committee for all 1000 patients enrolled in the trial. An interim analysis of the first 750 patients will be conducted and data forwarded to FDA.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
California
-
La Jolla, California, Forente stater, 92037
- Scripps Green Hospital/Scripps Clinic Torrey Pines
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Age 18 years or older
- Eligible for percutaneous coronary intervention
- Patient has at least one lesion ≥50% diameter stenosis requiring PCI with stenting
- Reference vessel diameter 2.25-4.0 mm
- Percutaneous intervention with use of one or more of the FDA approved CypherTM stents, planned not to exceed 108 mm of stent length.
- Target lesion is located within a native coronary artery or bypass graft
- De novo and restenotic lesions, including ISR, radiation failure
- Be reliable, cooperative and willing to comply with all protocol-specified procedures and follow-up
- Able to understand and grant informed consent
Exclusion Criteria:
- Confirmed pregnancy at the time of index PCI
- Has known allergies to aspirin, and to both clopidogrel (PlavixTM) and ticlopidine (TiclidTM)
- Has known allergies or contraindication to heparin and Bivalirudin (AngiomaxTM)
- Known allergy or sensitivity to any component of a Sirolimus-eluting stent
- Has a significant medical condition which in the investigator's opinion may interfere with the patient's optimal participation in the study;
- Any serious disease condition with life expectancy of less than 1 year.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
1 yr target vessel failure (TVF), defined as the occurrence of any of the following within 1-year after the index procedure: death from cardiac causes, Q-wave or non-Q wave MI attributable to the target vessel (TV), or revascularization of the TV.
Tidsramme: 1 year
|
1 year
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Paul S Teirstein, MD, Scripps Clinic
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Hjertesykdommer
- Kardiovaskulære sykdommer
- Vaskulære sykdommer
- Arteriosklerose
- Arterielle okklusive sykdommer
- Embolisme og trombose
- Koronar stenose
- Koronararteriesykdom
- Myokardiskemi
- Koronar sykdom
- Trombose
- Koronar restenose
- Koronar trombose
- Fysiologiske effekter av legemidler
- Anti-infeksjonsmidler
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Antibakterielle midler
- Antibiotika, antineoplastisk
- Antifungale midler
- Sirolimus
Andre studie-ID-numre
- 04-048
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Koronararteriesykdom
-
IRCCS Policlinico S. DonatoRekrutteringAnomalous aortic origin of the coronary artery (AAOCA)Italia
-
Medtronic CardiovascularFullførtArteriosclerosis of coronary artery bypass graftCanada, Forente stater
-
Lawson Health Research InstituteFullførtArteriosclerosis of arterial coronary artery bypass graftCanada
-
Deutsches Herzzentrum MuenchenFullførtArteriosclerosis of arterial coronary artery bypass graftTyskland
-
William Beaumont HospitalsFullførtKoronararteriesykdom | Arteriosclerosis of coronary artery bypass graftForente stater
-
Izmir Bakircay UniversityFullførtMyocardial Bridge of Coronary ArteryTyrkia
-
ITAB - Institute for Advanced Biomedical TechnologiesAzienda Ospedaliero, Universitaria Ospedali RiunitiFullførtMyocardial Bridge of Coronary ArteryItalia
-
University Hospital OstravaRekrutteringIn-Stent Carotis Artery RestenosisTsjekkia
-
Daewoong Pharmaceutical Co. LTD.UkjentMCA - Middle Cerebral Artery DissectionKorea, Republikken
-
University Hospital, ToulouseHar ikke rekruttert ennåFibromuskulær dysplasi av Wall of Carotid ArteryFrankrike
Kliniske studier på Sirolimus-Eluting Bx Velocity Coronary Stent (CypherTM Sirolimus-Eluting Stent)
-
Biotronik AGFullførtKoronararteriesykdomRomania
-
Concept Medical Inc.Aktiv, ikke rekrutterendeKoronararteriesykdom | Diabetes | Akutt koronarsyndromSveits, Australia, Korea, Republikken, Frankrike, Belgia, Nederland, Storbritannia, India, Østerrike, Bangladesh, Brasil, Tsjekkia, Tyskland, Irland, Italia, Malaysia, Mexico, Polen, Singapore, Sverige, Taiwan
-
Meril Life Sciences Pvt. Ltd.Lifecare Institute of Medical Sciences and Research Ahmedabad Gujarat...Fullført
-
Instituto Nacional de Cardiologia Ignacio ChavezRekrutteringKoronararteriesykdom | Sukkersyke | Akutt koronarsyndromMexico
-
Genoss Co., Ltd.RekrutteringKoronararteriesykdom | Medikamentavgivende stentKorea, Republikken
-
Cordis CorporationFullførtKoronararteriesykdomTyskland
-
Cordis CorporationFullførtKoronararteriesykdomBrasil
-
Advanced MedTech Solutions Pvt. Ltd.Har ikke rekruttert ennåKoronararteriesykdom | Koronar stentimplantasjon | De Novo stenoselesjon
-
Robbert J de WinterUkjentKoronararteriesykdomNederland, Latvia, Storbritannia, Luxembourg, Spania
-
Meril Life Sciences Pvt. Ltd.UkjentKoronararteriesykdomStorbritannia, Brasil, Spania, Makedonia, Den tidligere jugoslaviske republikken, Belgia, Tsjekkia, Latvia, Nederland, Polen